Testimony Of Baxter Int. CEO Before Subcommittee On Oversight And Investigations Committee On Energy And Commerce U.S. House Of Representatives
May 15th 2008Drug InformationBlood
SUMMARY OF MAJOR POINTS– More than any other company in the world, Baxter’s products are involved in critical caresettings. Because of this, we are greatly concerned that our heparin product appears to be thetarget of a deliberate adulteration scheme. Patient safety is our number one priority, and wedeeply regret the impact this contamination in Baxter’s heparin has had on patients and theclinicians who treat them.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
